# FDA WARNING_LETTER - Cipla Limited - February 17, 2023

Source: https://www.globalkeysolutions.net/records/warning_letter/cipla-limited/4a179ebd-255d-4805-a6d2-4e500633be4e

> FDA WARNING_LETTER for Cipla Limited on February 17, 2023. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Cipla Limited
- Inspection Date: 2023-02-17
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [483 - 2018-04-13](https://www.globalkeysolutions.net/records/483/cipla-limited/c8ec2a41-eca9-41c6-8e7d-d507b965a6dc)
- [WARNING_LETTER - 2019-09-27](https://www.globalkeysolutions.net/records/warning_letter/cipla-limited/6321f828-da26-4571-b32c-638dd2cf14df)
- [483 - 2022-07-01](https://www.globalkeysolutions.net/records/483/cipla-limited/e750f894-9f13-49ce-b379-c89e481f5245)
- [483 - 2023-02-17](https://www.globalkeysolutions.net/records/483/cipla-limited/72954a77-6423-4064-b768-46c816145d00)

## Related Officers

- [Director](https://www.globalkeysolutions.net/people/francis-godwin/1556d203-d47c-4744-af37-2591a163149e)
- [Compliance Officer - CDER/OC/OMQ](https://www.globalkeysolutions.net/people/anita-narula/fbebf5a2-e25c-4e98-9c22-433d9102380c)

Company: https://www.globalkeysolutions.net/companies/cipla-limited/de9dc5de-fbea-4a7d-ab5b-a398b6ed442e

Office: https://www.globalkeysolutions.net/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c